<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855136</url>
  </required_header>
  <id_info>
    <org_study_id>BB2121-MM-007</org_study_id>
    <secondary_id>2020-003248-10</secondary_id>
    <nct_id>NCT04855136</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma</brief_title>
  <acronym>KarMMa-7</acronym>
  <official_title>An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to&#xD;
      determine the safety, tolerability, efficacy, PK of bb2121 in combination with other&#xD;
      therapies in adult subjects with R/RMM.&#xD;
&#xD;
      The following combinations will be&#xD;
&#xD;
        -  Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone)&#xD;
&#xD;
        -  Arm B will test bb2121 in combination with BMS-986405 (JSMD194)&#xD;
&#xD;
        -  Arm C will test bb2121 in combination with one of the following standard triplet&#xD;
           regimens: 1) Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose&#xD;
           dexamethasone (DPd); 2) Pomalidomide (POM) in combination with bortezomib (BTZ) and&#xD;
           low-dose dexamethasone (PVd)&#xD;
&#xD;
      Combination agents being tested may be administered before, concurrently with and/or&#xD;
      following (ie, maintenance) bb2121 infusion.&#xD;
&#xD;
      The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose&#xD;
      expansion may occur in one or more arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does Limiting Toxicity (DLT) rates _Phase 1</measure>
    <time_frame>Up to 28 days from start of the combination therapy</time_frame>
    <description>Percentage of participants experiencing DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response Rate (CRR)_ Phase 2</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of participants who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by investigator's review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Event (AEs)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment</time_frame>
    <description>An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Proportion of participants who achieved PR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed investigator's review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first study treatment (whichever is given earlier) start date to the date of either first observation of progressive disease or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first study treatment (whichever is given earlier) start date to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first study treatment start date to the first date of documented response (PR or better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first documentation of response (PR or better) to first documentation of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next antimyeloma treatment (TTNT)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first study treatment (whichever is given earlier) start date to first day when participant receives another antimyeloma treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival after next antimyeloma therapy (PFS2)</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time from first study treatment (whichever is given earlier) start date to documentation of PD on the next-line treatment or death from any cause, whichever is first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of maintenance therapy in combination with bb2121</measure>
    <time_frame>Up to 4 months after bb2121 infusion in the respective cohort</time_frame>
    <description>Cumulative incidence of the maintenance therapy starting from bb2121 infusion with death as the competing risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax_Phase 1 and 2</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Maximum transgene level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax_Phase 1 and 2</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time to maximum observed transgene level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC_Phase 1 and 2</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Area under the curve of transgene level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-28days _Phase 1 and 2</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Area under the curve of transgene level from time 0 to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tlast _Phase 1 and 2</measure>
    <time_frame>Up to 24 months after the last participant received any study treatment in the respective cohort</time_frame>
    <description>Time of last measurable transgene level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">415</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B- bb2121 in combination with BMS-986405 (JSMD194)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agents will be administered as follow:&#xD;
Cohort 1 (DPd) DARA, POM and dexamethasone at M3D1 until disease progression.&#xD;
Cohort 2 (PVd) POM, BTZ and dexamethasone at M3D1 until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BB2121</intervention_name>
    <description>CAR T Cell Therapy</description>
    <arm_group_label>Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)</arm_group_label>
    <arm_group_label>Arm B- bb2121 in combination with BMS-986405 (JSMD194)</arm_group_label>
    <arm_group_label>Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib</arm_group_label>
    <other_name>ide-cel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)</description>
    <arm_group_label>Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986405</intervention_name>
    <description>gamma secretase inhibitor (GSI)</description>
    <arm_group_label>Arm B- bb2121 in combination with BMS-986405 (JSMD194)</arm_group_label>
    <other_name>JSMD194</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>immunomodulatory agent</description>
    <arm_group_label>Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>corticosteroids</description>
    <arm_group_label>Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>inhibitor of the proteasome</description>
    <arm_group_label>Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          -  Participant has documented diagnosis of MM and measurable disease, defined as:&#xD;
&#xD;
               1. M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis&#xD;
                  [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or&#xD;
&#xD;
               2. Light chain MM without measurable disease in the serum or urine: Serum&#xD;
                  immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum&#xD;
                  immunoglobulin kappa lambda free light chain ratio&#xD;
&#xD;
          -  Participant has received:&#xD;
&#xD;
               1. at least 3 prior MM regimens for Arm A Cohort 1 and Arm B&#xD;
&#xD;
               2. at least 1 but no greater than 3 prior MM regimens for Arm A Cohort 2 and Arm C.&#xD;
&#xD;
          -  Arm A Cohort 1 and Arm B: Participant has received prior treatment with an&#xD;
             immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody-containing&#xD;
             regimen for at least 2 consecutive cycles.&#xD;
&#xD;
          -  Arm A Cohort 2 and Arm C: Participant has received prior treatment with an&#xD;
             immunomodulatory agent for at least 2 consecutive cycles.&#xD;
&#xD;
          -  Evidence of PD during or within 6 months (measured from the last dose of any drug&#xD;
             within the regimen) of completing treatment with the last antimyeloma regimen before&#xD;
             study entry.&#xD;
&#xD;
          -  Participant achieved a response (minimal response [MR] or better) to at least 1 prior&#xD;
             treatment regimen.&#xD;
&#xD;
          -  Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#xD;
             or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a participant from enrollment:&#xD;
&#xD;
          -  Participant has non-secretory MM or has history of or active plasma cell leukemia,&#xD;
             Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.&#xD;
&#xD;
          -  Participant has any of the following laboratory abnormalities:&#xD;
&#xD;
               1. ANC and Platelets count as reported below&#xD;
&#xD;
               2. Hemoglobin &lt; 8 g/dL (&lt; 4.9 mmol/L) (transfusion is not permitted within 21 days&#xD;
                  of screening)&#xD;
&#xD;
               3. Creatinine clearance (CrCl) as reported below&#xD;
&#xD;
               4. Corrected serum calcium &gt; 13.5 mg/dL (&gt; 3.4 mmol/L)&#xD;
&#xD;
               5. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5&#xD;
                  ×upper limit of normal (ULN)&#xD;
&#xD;
               6. Serum total bilirubin &gt; 1.5 × ULN or &gt; 3.0 mg/dL for participants with documented&#xD;
                  Gilbert's syndrome&#xD;
&#xD;
               7. International normalized ratio (INR) or activated partial thromboplastin time&#xD;
                  (aPTT) 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or&#xD;
                  participant requires ongoing treatment with chronic, therapeutic dosing of&#xD;
                  anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)&#xD;
&#xD;
          -  Participant has inadequate pulmonary function defined as oxygen saturation (SaO2) &lt;&#xD;
             92% on room air.&#xD;
&#xD;
          -  Participant has known chronic obstructive pulmonary disease (COPD) with a forced&#xD;
             expiratory volume in 1 second (FEV1) 50% of predicted normal.&#xD;
&#xD;
          -  Prior exposure to CC-220 (± low-dose dexamethasone) as part of their most recent&#xD;
             antimyeloma treatment regimen (Arm A).&#xD;
&#xD;
          -  Prior exposure to, BMS-986405 (JSMD194) (Arm B).&#xD;
&#xD;
          -  Prior exposure to DARA in combination with POM with or without dexamethasone (DP±d) as&#xD;
             part of their most recent antimyeloma treatment regimen (Arm C Cohort 1).&#xD;
&#xD;
          -  Prior exposure to POM in combination with BTZ with or without dexamethasone (PV± d as&#xD;
             part of their most recent antimyeloma treatment regimen (Arm C Cohort 2).&#xD;
&#xD;
          -  Previous history of an allogeneic hematopoietic stem cell transplantation, treatment&#xD;
             with any gene therapy-based therapeutic for cancer, investigational cellular therapy&#xD;
             for cancer or BCMA targeted therapy.&#xD;
&#xD;
          -  Treatment Arm A Cohort 1 and Arm B: participant has received autologous stem cell&#xD;
             transplantation (ASCT) within 12 weeks prior to leukapheresis.&#xD;
&#xD;
          -  Treatment Arms A Cohort 2 and Arm C: participant has received autologous stem cell&#xD;
             transplantation (ASCT) within 12 months prior to leukapheresis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco Pittari, Md, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@bms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco- California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center Thomas Jefferson Univ</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Center for Blood Cancers</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Medical School</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitario de Salamanca - Hospital Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <keyword>BB2121</keyword>
  <keyword>ide-cel</keyword>
  <keyword>CC-220</keyword>
  <keyword>JSMD194</keyword>
  <keyword>BMS-986405</keyword>
  <keyword>DPd</keyword>
  <keyword>PVd</keyword>
  <keyword>CAR T</keyword>
  <keyword>KarMMa-7</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <keyword>DARA</keyword>
  <keyword>POM</keyword>
  <keyword>BTZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

